



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Sylvana MUELLER et al.

Application No.: 10/506,423

Group Art Unit: 1617

Filed: December 1, 2004

Examiner: CHONG, Yong Soo

For: USE OF UBIQUINONES FOR INFLUENCING HISTAMINE ACTIVITY

TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith please find:

- ☒ Response to Restriction Requirement
- ☐ Fee payment ☐ Payment Form PTO-2038 (credit card) for \$ is attached.
- ☐ Charge \$ to Deposit Account No. 06-1358.
- ☒ Small entity status established in connection with the subject application.

Fee Calculation					
Excess Claims					
	Nº of Claims	Highest Nº Paid For	Excess Claims	Small Entity Fee	Large Entity Fee
Total	*	⊖ * =	0	⊗ \$25 = \$	⊗ \$50 = \$
Ind.	*	⊖ * =	0	⊗ \$105 = \$	⊗ \$210 = \$
[] Multiple Dependent Claims (1 st Filing)				⊕ \$185 =	⊕ \$370 = \$
Excess Claims Fee				\$	\$
Extension of Time Fee				\$	\$
Other:				\$	\$
Total Fee Due				\$0	\$0

- ☒ If a petition for extension of time is necessary, but not enclosed, then this acts as the petition.
Charge any fees additionally necessary in connection herewith to Deposit Account No. 06-1358.

JACOBSON HOLMAN PLLC
400 Seventh Street, N. W.
Washington, D.C. 20004-2201
Tel. (202) 638-6666
Fax (202) 393-5350
Date: July 9, 2008
WEP/ms

By

William E. Player
Registration No. 31,409



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Sylvana MUELLER et al.

Application No.: 10/506,423

Group Art Unit: 1617

Filed: December 1, 2004

Examiner: CHONG, Yong Soo

For: USE OF UBIQUINONES FOR INFLUENCING HISTAMINE ACTIVITY

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:


This paper responds to the Office Action (restriction) mailed June 11, 2008.

Pursuant to the restriction requirement under 35 USC §121, election is made, hereby, to prosecute invention Group III, claims 5-8, drawn to a method for influencing the activity of histamines and other mediators with ubiquinones, without traverse.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By:


William E. Player
Reg. No. 31,409

400 Seventh Street, N.W.
Washington, D.C. 20004-2201
Tel.: 202-638-6666
Fax: 202-393-5350
Date: July 9, 2008
WEP/ms